Cutaneous malignancy and human immunodeficiency virus disease - 09/08/11

Doi : 10.1016/j.jaad.2004.11.060

Karl Wilkins, MD ^a,^⁎ , Ryan Turner, MD ^b, Jacqueline C. Dolev, MD ^a, Philip E. LeBoit, MD ^a, Timothy G. Berger, MD ^a, Toby A. Maurer, MPH, MD ^a
^a From the Departments of Dermatology at the University of California–San Francisco
^b Harvard Medical School

Reprint requests: Karl Wilkins, MD, San Francisco General Hospital, Department of Dermatology, 1001 Potrero Ave #224, Ward 92, San Francisco, CA 94110.

San Francisco, California, and Boston, Massachusetts

Abstract

Certain skin cancers occur with increased frequency or altered course in patients infected with HIV. Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV. Others, such as basal cell carcinoma, appear more frequently in this population but do not appear to be more aggressive. The incidence of HIV-associated Kapsosi’s sarcoma has markedly decreased since the advent of HIV antiretroviral therapy. Our understanding of the pathogenesis of this malignancy and its unique management issues are fully reviewed. Cutaneous T-cell lymphoma (CTCL) is rare in this population. Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed. This article addresses prevention, treatment, and follow-up strategies for this at-risk population.

Learning objective

At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : ART, BCC, CTCL, EBV, HD, HHV-8, HPV, HTLV, KS, MF, MM, MSM, NHL, Pap, SCC, SIL